Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry PerspectiveTonika Bohnert, Y.-H. Wang, Michael Sinz et al.|Drug Metabolism and Disposition|2016Cited by 110
Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical AnalysesYasong Lu, Martin Pettersson, David Riddell et al.|Journal of Pharmacology and Experimental Therapeutics|2012Cited by 36
Cerebrospinal Fluid β-Amyloid Turnover in the Mouse, Dog, Monkey and Human Evaluated by Systematic Quantitative AnalysesYasong Lu, David Riddell, Hugh A. Barton et al.|Neurodegenerative Diseases|2012Cited by 21
Front & Back MatterRobert Christian Wolf, Satz Mengensatzproduktion, Philipp A. Thomann et al.|Neurodegenerative Diseases|2013Cited by 0